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Abstract
Background: Non-small cell lung cancer (NSCLC) patients with L858R or exon 19 deletion mutations in epidermal growth
factor receptor (EGFR) have good responses to the tyrosine kinase inhibitor (TKI), gefitinib. However, patients with wild-type
EGFR and acquired mutation in EGFR T790M are resistant to gefitinib treatment. Here, we showed that curcumin can
improve the efficiency of gefitinib in the resistant NSCLC cells both in vitro and in vivo models.
Methods/Principal Findings: After screening 598 herbal and natural compounds, we found curcumin could inhibit cell
proliferation in different gefitinib-resistant NSCLC cell lines; concentration-dependently down-regulate EGFR phosphory-
lation through promoting EGFR degradation in NSCLC cell lines with wild-type EGFR or T790M EGFR. In addition, the anti-
tumor activity of gefitinib was potentiated via curcumin through blocking EGFR activation and inducing apoptosis in
gefitinib-resistant NSCLC cell lines; also the combined treatment with curcumin and gefitinib exhibited significant inhibition
in the CL1-5, A549 and H1975 xenografts tumor growth in SCID mice through reducing EGFR, c-MET, cyclin D1 expression,
and inducing apoptosis activation through caspases-8, 9 and PARP. Interestingly, we observed that the combined treatment
group represented better survival rate and less intestinal mucosal damage compare to gefitinib-alone therapy. We showed
that curcumin attenuated the gefitinib-induced cell proliferation inhibition and apoptosis through altering p38 mitogen-
activated protein kinase (MAPK) activation in intestinal epithelia cell.
Conclusions/Significance: Curcumin potentiates antitumor activity of gefitinib in cell lines and xenograft mice model of
NSCLC through inhibition of proliferation, EGFR phosphorylation, and induction EGFR ubiquitination and apoptosis. In
addition, curcumin attenuates gefitinib-induced gastrointestinal adverse effects via altering p38 activation. These findings
provide a novel treatment strategy that curcumin as an adjuvant to increase the spectrum of the usage of gefitinib and
overcome the gefitinib inefficiency in NSCLC patients.
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Introduction
Lung cancer is the leading cause of cancer death in the United
States and worldwide [1,2]. Approximately 85% of lung cancer
patients belong to the non-small-cell lung cancer (NSCLC) group
with a poor prognosis [3]. Previous study showed that the
epidermal growth factor receptor (HER1/EGFR) overexpression
rate is 40-80% in NSCLC and plays the key role in tumorigenesis
[4]. In addition, EGFR-driven cell signaling contributes to the
disease progression and cancer malignancy [5]. These offer an
effective therapeutic target to develop agents for NSCLC [6].
Gefitinib, EGFR tyrosine kinase inhibitor (TKI), was the first
selective small molecular agent showed the effective activity in
blocking EGFR phosphorylation and downstream signaling and
approved for NSCLC treatment [7,8]. Previous multi-institutional
clinical trial studies indicated the response to gefitinib is better in
Asian patients compared to Caucasian patients and that women
who are non-smokers and have adenocarcinoma are the most
likely to benefit the most [9,10]. In addition, recent studies showed
the pharmacogenomic issues in EGFR determine the limitation of
gefitinib in clinical applications: Activating mutations of the in-
frame deletions (DE746-A750) in exon 19 and the L858R point
mutation in exon 21 of the EGFR tyrosine kinase domain in
NSCLC are highly correlated with gefitinib sensitivity [11,12,13].
However, the activating mutations rate has been found in range
from 10% to 15% in Caucasians and from 30% to 40% in Asians
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23756among the NSCLC patients [14,15]. In addition, acquired
resistance caused by a second site substitution, T790M in exon
20, results in poorly gefitinib activity [16,17]. Thus, it is important
and urgent to develop new agents or pinpoint novel approaches
for improving the anti-tumor effects of gefitinib in NSCLC
patients.
By screening the 598 herbal and natural compounds containing
the range of alkaloids, sesquiterpenes, diterpenes, pentacyclic
triterpenes, sterols and many other diverse representatives
purchased from Sigma and ChromaDex to the different
gefitinib-resistant NSCLC cell lines through cell proliferation
assay, we tested one of the hits curcumin (diferuloylmethane) as the
candidate may be a potential agent to accomplish our goal. We
have previously shown that curcumin could inhibit cell cycle
progression, induce cell apoptosis and anti-metastasis by regulating
various mechanisms in different cell types [18,19,20]. Recent
studies indicated that curcumin was able to down-regulate EGFR
and HER2/neu protein kinase activity which inhibits the cancer
cells growth [21,22,23]. In addition, curcumin has been reported
to suppress the growth of human colon cancer-derived Moser cells
by reducing EGFR genes expression [24]. Curcumin also down-
regulates EGFR signaling in prostate cancer cells by modulating
levels of EGFR protein showing that curcumin inhibits the
intrinsic EGFR tyrosine kinase activity and suppress ligand-
induced activation of EGFR [25]. Furthermore, clinical trials have
indicated that no dose-limiting toxicity when curcumin is
administered at doses up to 10 g/day and the serum concentration
of curcumin was 1.7761.87 mM at the dose of 8 g/day [26].
Thus, curcumin may have enormous potential and relative cheap
and safe in cancer therapy combined with other treatments to
NSCLC.
Although the anticancer mechanisms of curcumin and the
antineoplastic activities of curcumin combined with several clinical
used antitumor drugs have been documented, the potential effects
of curcumin combine with gefitinib in NSCLC have not been
evaluated. In the present study, we determine curcumin as a
potential agent by the high-throughput drug screening and
examine that curcumin suppress EGFR activation was resulted
from accelerating EGFR protein degradation. We next investigate
the effectiveness of curcumin on anti-tumor effects of gefitinib in
NSCLC in vitro and in vivo. We reveal that curcumin enhances the
anti-tumor effects of gefitinib in various resistant NSCLC cancer
cell lines by modulating the EGFR protein kinase activity which
leads to reduce the cancer cells growth ability and promotes cell
apoptosis in vitro. Besides, curcumin also significantly potentiates
the anti-tumor properties of gefitinib in gefitinib-resistant cancer
cells bearing subcutaneously tumors in SCID mice. Interestingly,
we observe that curcumin significantly reduces the gastrointestinal
(GI) adverse effect of gefitinib in xenografts model. We find that
curcumin significantly attenuates the gefitinib-induced GI damage
and resulted in a better survival rate with less damage to the villi
might through modulating p38 activation.
Results
Curcumin inhibits cell proliferation in gefitinib-resistant
lung adenocarcinoma cells and induces endogenous
EGFR protein degradation
To screen the potential hits which can overcome the gefitinib
resistance, several gefitinib resistance NSCLC cell lines, including
CL1-5 (EGFR
wt), A549 (EGFR
wt), H1299 (EGFR
wt), H1650
(EGFR
19del) and H1975 (EGFR
L858R+T790M) were used, which
showed an overall pattern of increased resistance when incubated
with gefitinib for 72 h (IC50=15–20 mM for CL1-5, A549, H1299
and H1975, H1650 is higher than 20 mM), compared with the
gefitinib-sensitive cell lines, PC-9 (EGFR
19del)(IC50=30 nM)
(Figure 1A), Screening 598 herbal and natural compounds; we
obtained 26 potential candidates such as curcumin, emetine,
shikonin and tomatine (data not shown). Further validation
showed curcumin significantly inhibits cell proliferation with no
difference in EGFR status of these gefitinib-resistant lung
adenocarcinoma cells in a concentration-dependent manner
(Figure 1B).
In terms of the EGFR is highly correlated with the tumor
progression in lung cancer [4,5], wild-type EGFR is the main
population among the NSCLC cases, and EGFR T790M results in
TKIs resistance [14,15,16,17]. The effects of curcumin on EGFR
activation in CL1-5, A549 and H1975 cells were examined. Our
results indicated that the starved cells pre-treated with curcumin (0–
20 mM) and then stimulated with 20 ng/ml EGF for 3 h showing
the concentration-dependently reduced phospho-EGFR protein
levels in these NSCLC cell lines; interestingly, the endogenous
EGFR were also dramatically depleted (Figure 1C). To investigate
the possible mechanism underlying curcumin-induced EGFR
depletion, we examined whether curcumin accelerates EGFR
degradation and results in EGFR protein destabilization. Treating
CL1-5 cells with the protein synthesis inhibitor, cycloheximide
(100 mg/ml), the EGFR protein level decreased slowly; whereas,
curcumin can quickly induce EGFR depletion to 10% in 15 min
(Figure 2A). Interestingly, the curcumin-induced EGFR degrada-
tion in CL1-5, A549, and H1975 cells all in the concentration-
dependent manner, and at least, in part, through proteasome-
dependently; whereas, Figure 1D showed that the proteasome
inhibitor, MG132 (10 mM), can partially recover the curcumin-
induced EGFR degradation (Figure 2B). Furthermore, the
immuno-precipitation data showed that curcumin may induce
EGFR protein degradation through ubiquitination of wild-type
EGFR (CL1-5 and A549 cells) and also in the mutated EGFR with
T790M (H1975 cells) (Figure 2C). These results indicated that
curcumin-induced EGFR degradation may go through accelerating
ubiquitin-proteasome ability in the gefitinib-resistant cells.
Curcumin potentiates the anti-cancer effects of gefitinib
in human lung adenocarcinoma cells in vitro
Curcumin showed potential effects on inhibiting cancer cell
proliferations and can induce EGFR degradation in gefitinib-
resistant NSCLC cell lines. Previous study indicated that curcumin
has been shown to have therapeutic effects against cancer and may
play a ideal agents for cancer therapy [27]. We hypothesized that
curcumin may enhance the anti-cancer effects of gefitinib on these
resistant cell lines; including CL1-5, A549 and H1975 cell lines
(the IC50 of these cell lines to gefitinib are 10–15 mM). Curcumin
exhibited to sensitize the anti-proliferative ability of gefitinib of all
three gefitinib-resistant cell lines, and the combination of curcumin
and gefitinib was equivalent in cell viability to the high-dose
gefitinib (Figure 3A). Combination index (CI) isobologram was
also calculated as descript in ‘‘Material and Methods’’ and showed
that combination treatment with curcumin and gefitinib synergis-
tically in CL1-5 (EGFR
wt)(CI=0.45), A549 (EGFR
wt)(CI=0.41),
H1299 (EGFR
wt)(CI=0.66), and H1650 (EGFR
19del)(CI=0.83);
whereas, approximately addictive in H1975 (EGFR
L858R+T790M)
cell line (CI=1.02). Furthermore, combination treatments with
curcumin (10–15 mM) and gefitinib (1 mM) can almost complete
blockage the EGFR activation in the three gefitinib-resistant cells
(CL1-5, A549 and H1975 cell lines) (Figure 3B).
To examine whether curcumin can increase gefitinib-induced
cell apoptosis in the gefitinib-resistant cell lines, flow cytometry
assay with propidium iodide/annexin-V staining was used, and the
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curcumin induced more apoptotic cells than 20 mM gefitinib in
CL1-5 and A549 cells (Figure 3C). Curcumin showed most
effectively on H1975 cells; since curcumin can induce around 90%
of cell apoptosis in H1975 cell with or without gefitinib.
We next examined whether curcumin enhances the anti-
tumorigenicity of gefitinib in the gefitinib-resistant cell lines using
a colony formation assay. The results showed that combination of
1t o1 5mM curcumin and 1 mM gefitinib significantly inhibited
colony formation by CL1-5, A549 and H1975 compared to the
drug-free control and either gefitinib (1–15 mM) or curcumin (1–
15 mM) treatment alone, respectively (Figure 3D).
Curcumin enhances the antitumor properties of gefitinib
in human lung adenocarcinoma cells xenografts in vivo
To assess whether curcumin potentiates the antitumor activity
of gefitinib in vivo, we examined the effects of curcumin and
gefitinib on the tumor growth of the CL1-5, A549 and H1975
gefitinib-resistant cells via the xenografts model. We injected the
cells subcutaneously into the mice; the mice were randomized and
Figure 1. Curcumin inhibits cell proliferation and down-regulates EGFR activation in gefitinib-resistant NSCLC cell lines. (A) MTT
assay results showed susceptibility of gefitinib in all six lung adenocarcinoma cell lines. Columns, mean (n=6); bars, SEM. Data are representative of
two independent experiments. (B) MTT assay analysis showed curcumin harbored dose-dependent suppression of cell proliferation in five gefitinib-
resistant NSCLC cell lines. Columns, mean (n=6); bars, SEM. Data are representative of two independent experiments. (C) Western blotting analysis
showed curcumin decrease the EGF (20 ng/ml)-induced EGFR and pEGFR, expression in CL1-5, A549 and H1975 cells in a dose-dependent manner (1–
20 mM). b-actin used as the internal control and the numbers below the row of the EGFR and pEGFR indicate the densitometric values normalized
with the relative b-actin value.
doi:10.1371/journal.pone.0023756.g001
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kg), and curcumin combination with gefitinib once daily orally
after one week. Tumor volume from CL1-5 and H1975 xenografts
mice were monitored per 4 days showing the similar results in the
control group were gradual increased comparing with the other
treatment groups (Figure 4A, left and 4B, left). The tumor volume
in the combination group was significantly lower than the control
group and showed the more inhibitory ability in tumor growth
compared to the gefitinib versus vehicle control. Because the
combined effect was the greatest in CL1-5 cell in vitro, we added
one more treatment strategy in this xenograft model. The half-
dose of the gefitinib (60 mg/kg) combined with curcumin showed
the equal inhibitory effectiveness to the 120 mg/kg gefitinib alone
group in the CL1-5 xenograft tumor volume. We monitored the
tumor volumes on the last day of the experimental design
indicated that the tumor volumes were statistically significant
decreased in the combination groups compared with the vehicle
control (60 mg/kg gefitinib combined with 1 g/kg curcumin
Figure 2. Curcumin potentially modulates EGFR expression by accelerating protein degradation in gefitinib-resistant NSCLC cell
lines. (A) Analysis the half-life of EGFR protein level in 100 mg/ml cycloheximide treated CL1-5 cells with or without 10 mM curcumin by Western
blotting. (B) Western blotting analysis revealed that MG132 recover the EGFR level of the curcumin-affected EGFR protein depletion. b-actin used as
the internal control and the numbers below the row of the EGFR indicate the densitometric values normalized with the relative b-actin value. (C)
Detection of ubiquitin (Ub) levels by immunoprecipitation of EGFR in CL1-5, A549 and H1975 cells showed the elevation of poly-Ub expressions in the
presence of curcumin (10–15 mM). Ub and EGFR levels were measured by Western blotting.
doi:10.1371/journal.pone.0023756.g002
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formation of gefitinib in gefitinib-resistant in NSCLC in vitro. (A) MTT assay results showed curcumin enhanced the anti-proliferative effect of
gefitinib in CL1-5, A549 and H1975 gefitinib-resistant lung adenocarcinoma cell lines. Columns, mean (n=6); bars, SEM. **, P,0.01. Data are
representative of two independent experiments. (B) Western blotting analysis showed curcumin improve the blockage of EGF (20 ng/ml)-induced
EGFR and pEGFR expression of gefitinib in CL1-5, A549 and H1975 cell lines. b-actin used as the internal control and the numbers below the row of
the pEGFR indicate the densitometric values normalized with the relative b-actin value. (C) Annexin V-FITC apoptosis assay results showed curcumin
enhance the apoptotic effect of gefitinib, CL1-5 cell was treated agents as indicating. The x axis is Annexin-V-FITC, and the y axis is PI (propidium
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120 mg/kg gefitinib combined with 1 g/kg curcumin P=0.0028
versus control in H1975 xenograft; Figure 4B, right). In addition,
the effects on the combination groups versus control exhibited
further growth inhibition in tumor volumes comparing to the
gefitinib alone versus control in H1975 xenograft (P=0.0028 and
0.02, respectively; Figure 4B, right). The results also indicated that
the tumor volumes in 60 gefitinib combined with 1 g/kg curcumin
group compare with 120 mg/kg gefitinib alone group in the CL1-
5 xenograft was no significantly different (P=0.484 versus
gefitinib; Figure 4A, right).
We also evaluated the effects of curcumin and gefitinib in the
growth of tumor volumes in A549 expressing luciferase xenograft
model using IVIS imagining. Tumor volumes were monitored per
7 days and the bioluminescence imaging results (Figure 4C, left)
indicated the significant lower in tumor volume of the gefitinib and
combination group compared with the control group (P=0.019
versus control). The results also showed that combination group
significantly decreased the tumor volumes compared with the
gefitinib alone to the vehicle control (P=0.019 versus P=0.146,
respectively). The final tumor volumes on day 42 showed
significant decrease in the combination group compared with
vehicle control (P=0.0013 versus control) and with gefitinib alone
group (P=0.025 versus gefitinib) (Figure 4C, right).
Curcumin down-regulates EGFR, AKT, c-MET cyclin D1
and PCNA proteins expression, and induces apoptosis
activation in CL1-5 xenograft tumors
To examine whether curcumin potentiates antitumor effect of
gefitinib on the tumor growth is associated with down-regulation
of the tumor progression related oncogenic proteins expression in
tumor tissues from four groups of CL1-5 xenograft. We tested the
EGFR, AKT, c-MET cyclin D1 and PCNA proteins expression
using Western blotting. The results showed the protein levels of
EGFR and AKT were decreased in the tumor homogenates in
both curcumin alone and curcumin combined with gefitinib
groups, whereas, the c-MET, cyclin D1, and PCNA were also
down-regulated simultaneously (Figure 5A).
To investigate whether curcumin sensitizes the apoptosis-
inducing effects of gefitinib in CL1-5 xenograft tumors, the
apoptosis-related protein caspase 8 and 9, and PARP were
examined by Western blotting. The results showed that curcumin
enhanced the activity levels of caspase-8, caspase-9 and PARP
showing the decrease amounts of pro-caspase-8, pro-caspase-9,
pro-PARP, and increasing the c-PARP, especially in the
combination group (Figure 5B).
We next confirm the Western blotting results using immuno-
histochemical staining and cell apoptosis detection assay in CL1-5
xenograft tumor tissues. We examined that the PCNA-positive
cells were decreased, which indicated the reduction of proliferated
cells, in the curcumin treated and in the curcumin combined with
gefitinib treated groups. In addition, the results showed that
treatment with curcumin combined with gefitinib significantly
increased cell apoptotic activities, TUNEL-positive cells, com-
pared to the control and to the gefitinib groups (Figure 5C).
Curcumin reduces the gefitinib-induced villi damage and
apoptosis in mice intestines
During the in vivo xenograft study, we observed that the
120 mg/kg gefitinib-treated mice suffered the diarrhea side effect;
this is similar to previous reports in clinical literature [28,29] and
was even severely to cause death within the group. We measured
that the 22.1760.18% body weight lost compared to the vehicle
control group and there was also an obviously diarrhea side effect.
The body weight didn’t alter in the curcumin group as well as
vehicle control. Interestingly, we found that the combination
group showed to prevent the body weight loss at the last day of the
study (13.1960.15% loss comparing to the control groups) (data
not shown) and significantly reduced the number of deaths among
the mice (combination group was 78% compared with 33% for the
gefitinib) (Figure 6A). We next examined the histological
morphology in intestine tissues from four groups of the xenograft
mice using H&E staining. The results in Figure 6B showed that the
villus of the intestine tissues in the gefitinib group was shorter and
looser than in the combination group. The length of villi in
curcumin and gefitinib combined group were longer and had
greater integrity compared to gefitinib group (P=0.0001).
We next tested whether curcumin reduces the gefitinib-induced
apoptosis effects in the mice villi from four groups. The results
indicated that curcumin combined with gefitinib significantly
reduced the expression of TUNEL-positive cells in intestine villi
compared with the gefitinib group (P=0.0015) (Figure 6C and D).
Curcumin attenuates the adverse gastrointestinal effects
of gefitinib by modulating p38 activation
To determine the possible mechanism of the effect of curcumin
treatment on reducing gefitinib-induced damage, we used the non-
transformed intestinal epithelial cell line IEC-18 to assess the
protective effects of curcumin. We examined whether gefitinib
might induce apoptosis in IEC-18 cell line measuring by caspase
3/7 activation (Caspase-Glo assay). The results showed that
gefitinib (IC25 at 30 mM and IC50 at 40 mM of gefitinib to IEC-18
cell, respectively) induced caspase 3/7 activities in IEC-18 cell,
whereas, 5 mM curcumin (non-toxic dosage) significantly inhibited
the gefitinib-induced caspase 3/7 activities (Figure 7A). To study
the possible mechanisms involve in this protective effect of
curcumin on gefitinib-induced apoptosis, we found that the
previous reports has indicated that gefitinib induced apoptosis in
intestinal epithelial cells via p38 MAPK-dependent activation [30].
Herein, the results showed the active-p38 significantly increased in
a dose dependent manner of gefitinib (0–20 mM) treatment in
IEC-18 cell by Western blotting (Figure 7B), but not in the
NSCLC cell lines (data not shown).
We next examined whether curcumin reduces the gefitinib-
induced p38 activation and results in the better cell viability. The
Western blotting results (Figure 7C) showed that curcumin (5 mM)
iodide) for all graphs represented; CL1-5, A549 and H1975 cells undergoing apoptosis were statistically counted the Annexin-V
+ and PI
- levels of total
cells in the lower right quadrant. Columns, mean (n=3); bars, SD. *, P,0.05, **, P,0.01 and P=0.331 (15 mM curcumin versus 1 mM gefitinib plus
15 mM curcumin). Data are representative of triplicate independent experiments. (D) Colony formation assay analysis represented curcumin enhance
the colony inhibitory ability of gefitinib in CL1-5, A549 and H1975 cells. Cells cell was treated agents as indicating; V: vehicle control, G1, G5, G10, G15,
C1, C5, C10, C15, G1+C1, G1+C5, G1+C10 and G1+C15: G and C indicated gefitinib and curcumin, and number showed the concentrations (mM) of the
agents, respectively; Colony formation index (%) was expressed as the percent of cells number in the each groups compared to the vehicle control.
Colonies were counted after 2 weeks of the experiment using crystal violet staining. Columns, mean (n=3); bars, SD. Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0023756.g003
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activation in IEC-18 cell. The results also indicated that curcumin
and the selective p38 MAPK inhibitor BIRB 796 (10 nM)
decreased the active-p38 expression in gefitinib-treated IEC-18
cells. To examine whether curcumin sustains the viability in the
presence of gefitinib in vitro, we assessed the MTT assay to
determine the effect of curcumin on the gefitinib-treated IEC-18
cell. The results showed that gefitinib (30 and 40 mM) reduced
IEC-18 cell survival, whereas, curcumin (5 mM), as well as the
BIRB 796 (10 nM), significantly rescued the cells from this toxic
effect of gefitinib (Figure 7D).
Discussion
Curcumin has long been known as a potential therapeutic or
preventive agent for several major human cancers [31,32], by
regulating multiple targets on tumor signaling pathways, such as
protein kinases, transcriptional factors and apoptosis-related
proteins [20,33,34,35,36,37]. Also, since curcumin displayed
synergistic effects of several chemotherapeutic drugs, it has been
suggested as an adjuvant for anti-cancer therapy [36,38,39,40,41].
However, the potential anti-tumor effect of curcumin combined
with EGFR-TKIs on NSCLC has not yet been investigated. In the
present work, we found that curcumin has dual beneficial effects
on gefitinib therapy in NSCLC (Figure 8). Curcumin can sensitize
cancer cells to gefitinib therapy in NSCLC with different EGFR
status through accelerating EGFR ubiquitination; also, curcumin
can attenuate gefitinib-induced gastrointestinal adverse effects via
altering p38 activation and reducing cell apoptosis in intestinal
epithelial cells. We suggest curcumin could be clinically applicable
as an adjuvant to increase the applications of EGFR-TKIs therapy
in NSCLC patients with different EGFR status. This is the first
report to show that curcumin can overcome the gefitinib
inefficiency and inhibited EGFR protein kinase activity through
down-regulating endogenous EGFR level via accelerating protea-
some-ubiquitin activity. In addition, we showed that curcumin
promoted gefitinib-induced cell apoptosis in the xenograft NSCLC
tumor growth model via inducing caspase and PARP activation.
The hypothetic scheme of curcumin enhanced anticancer effects
of gefitinib on lung adenocarcinoma was shown in Figure 8.
Our results indicated that curcumin significantly reduced not
only pEGFR, but also EGFR protein expression in a concentra-
tion-dependent manner. Although previous studies have indicated
that curcumin inhibited EGFR kinase activity and block ligand-
induced EGFR activation in the different types of cells [21,22],
these reports showed the amount of EGFR did not alter in the
presence of curcumin. Our results found that curcumin can
decrease EGFR protein expression might through down-regulated
EGFR protein in gefitinib-resistant NSCLC cells. Even the
MG132 treatment did not completely recovered the EGFR
protein level in the presence of curcumin, we indicated that
curcumin contributed to alter the EGFR stability and sensitized
the NSCLC to gefitinib. Recently, the evidence indicated that
curcumin can down-regulate EGFR protein expression as well as
the function of Hsp90 inhibitor via the ubiquitin-proteasome
pathway [42]. The molecular chaperone Hsp90 is a potential
target for cancer treatment and regulates the client protein
activation and stability such as self-sufficiency in growth signals,
evasion of apoptosis, acquisition of limitless, insensitivity to
antigrowth signals, invasion and metastasis and sustained angio-
genesis [43]. Our data showed that curcumin down-regulated the
EGFR expression in a dose-dependent manner were similar to the
previous reports on the role played by Hsp90 inhibitor in the
gefitinib-resistant NSCLC cell lines [44,45,46]. In addition, our
results showed that Hsp90 client proteins: AKT, c-MET and
cyclin D1 expressions were inhibited by curcumin in the
xenografts model as well as the effect of Hsp90 inhibitor. Thus,
these results suggested curcumin sensitized gefitinib and overcame
the gefitinib resistance in modulating EGFR or other oncogenic
proteins stability might similar to the actions of the Hsp90
inhibitor in which contributed to the NSCLC therapy (Figure 8).
Recent studies have described that cyclin D1 is a key driver of
malignant transformation [47], and c-MET amplification leads to
acquired TKIs resistance in NSCLC [48,49]. Previous research
exhibited that curcumin suppressed NF-kB-regulated proteins
control cancer cell progression and these include cyclin D1 [33,36]
and blocked the transactivation of AP-1 on the MET promoter
[50]. Our results showed that curcumin down-regulated cyclin D1
and c-MET expression in lung adenocarcinoma xenograft tissues.
Thus, our results indicated curcumin may be an alternative
therapeutic agent to combine with gefitinib for altering cyclin D1
and c-MET activation in acquired gefitinib-resistant NSCLC.
In the present study, we showed that curcumin combined with
low dose gefitinib (1 mM) exhibited more anticancer activities as
comparing with high dose of gefitinib (10–20 mM) treatment in
inhibiting cell proliferation, decreasing colony formation ability
and inducing apoptosis of these gefitinib-resistant lung adenocar-
cinoma cell lines in vitro. Besides, in CL1-5 xenograft mice model,
half dose of gefitinib (60 mg/kg) plus curcumin group has similar
anticancer activity in tumor growth to the 120 mg/kg gefitinib
group. This is the first report indicates the potential of curcumin as
an effective agent combine with gefitinib enhancing the antitumor
activities, our data offer a potentially benefit for clinical application
of curcumin in reducing the dosage of gefitinib. It might cut down
the cost of targeted therapy drug gefitinib and abating the burden
of patient and public health insurance. Due to the low absorption
efficacy of curcumin, the dosage was used up to 1 g/kg. Although
there is no toxic response observed during the whole experimental
periods comparable to the previous study [36], this is still an issue
for clinical application to exhibit sufficient beneficial effects of
curcumin. Solving this problem, to innovate the novel preparation
or analogs of curcumin for improving oral bioavailability was
developed to prolong the half-life, reduce the dosage and improve
the effectiveness of curcumin [51,52,53]. From the herbal and
Figure 4. Curcumin sensitizes the effect of gefitinib in inhibiting the growth of gefitinib-resistant NSCLC in SCID mice. (A) left,1 0
6
CL1-5 cells were implanted s.c. in SCID mice and tumor volumes were monitored over time. Points, mean (n=6); bars, SD; right, tumor volume in CL1-
5 xenograft were measured on the last day of the experiment using vernier calipers. Columns, mean (n=6); bars, SD. P=0.0003 (control versus
gefitinib), 0.0006 (control versus 1 g/kg and 60 mg/kg gefitinib) and 0.484 (1 g/kg and 60 mg/kg gefitinib versus gefitinib). (B) left,1 0
6 A549
xenograft study processed as well as the methods in CL1-5 xenograft. Points, mean (n=6); bars, SD; right, tumor volume in A549 xenograft were
measured on the last day of the experiment using vernier calipers. Columns, mean (n=6); bars, SD. P=0.0028 (control versus combination), 0.02
(control versus gefitinib). (C) left, bioluminescence IVIS images of A549 xenograft mice were visualized in anesthetized animals after i.p. inoculation of
D-luciferin. The photon flux were measured per second and depicted as the tumor volume at the indicated time using IVIS imaging. Points, mean
(n=6); bars, SD. P=0.019 (control versus combination), 0.146 (control versus gefitinib). right, tumor volume in H1975 xenograft were measured on
the last day of the experiment using vernier calipers. Columns, mean (n=6); bars, SD. P=0.0013 (control versus combination), 0.016 (control versus
gefitinib) and 0.025 (gefitinib versus combination). The xenograft protocols were detail described in Materials and Methods.
doi:10.1371/journal.pone.0023756.g004
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hit of curcumin in NSCLC in our study, we suggests that curcumin
might be an ideal leading compound for drug development or as
an adjuvant in the NSCLC treatment.
The evidence in previous xenografts study indicated that at the
maximum tolerated dose (150 mg/kg) of gefitinib showing 70–
80% growth inhibition again A549 tumor and the body weight
was 10% after qd65 for two weeks treatment in mice [54]. In the
present study, 120 mg/kg gefitinib was used as the high dose
treatment and 60 mg/kg as the lower dose to test the effects on
tumor growth in the alone or combined with curcumin treatment
in gefitinib-resistant cell lines xenograft. Although the results
indicated the tumors growth inhibition were different in the three
gefitinib-resistant NSCLC cell lines xenografts after gefitinib alone
treatment; whereas, combination with curcumin showed the
significant regression in tumor growth compared with gefitinib
alone.
In the present work, the high dose of gefitinib (120 mg/kg)
caused the reduction of the survival rate in mice after the third
week treatment and the body weight loss were significantly and
observably severe diarrhea compared to the other groups. Previous
reports have shown that treatment with gefitinib always leads to
diarrheal side effects in patients [28,29], which opens up to
question as to what is the possible mechanism of the GI side effects
of gefitinib and how combination treatment with curcumin can
rescue the survival rate? Recent studies indicated that diminish
EGFR activity initiates the intrinsic pathway of cell apoptosis
accompanied by rapid phosphorylation of p38 and Bax activation
in intestinal epithelial cells. [30], but gefitinib did not influence the
expression or phosphorylation state of p38 in NSCLC in vitro and
in vivo [55,56]. In addition, curcumin has been discovered as a p38
modulator [57,58]. These studies may provide the possible hint for
us to solve the gefitinib-related adverse effect problem in the GI.
The hypothetic scheme of curcumin attenuated the gefitinib-
induced apoptosis on intestinal epithelial cells in this study was
shown in Figure 8. Our result is the first report to show that
curcumin significantly attenuated the gefitinib-induced diarrheal
side effect, prevented the loss of integrity of the intestine villi and
reduced apoptosis in the intestine in vivo. In addition, the intestinal
epithelial cells protective effects of curcumin can be validated in
vitro in the IEC-18 rat intestinal epithelial cell line by reducing the
gefitinib-induced apoptosis and preserve cell viability in the
presence of gefitinib might through modulating p38 activation,
comparable to other previous findings showed that curcumin can
protect intestinal mucosa barrier and other related intestinal
diseases through inhibition of p38 and NF-kB activation,
modulating IL-10, IL-b, and MMP-3, and other anti-inflamma-
tory and anti-oxidant activities [59,60].
In conclusion, our novel findings suggest that curcumin, a
natural food substance with no known human toxicity, holds
promise as an adjuvant to broaden the spectrum of gefitinib
therapy to improve the efficacy of gefitinib among the NSCLC
patients with different EGFR status. Our finding is the first report
showing curcumin is able to exhibit the prominent activity which
enhances anti-tumor abilities of gefitinib in vitro and in vivo by
modulating EGFR stability. Curcumin also attenuates gefitinib-
induced GI damage by modulating p38 activation. To overcome
the gefitinib inefficiency and to prevent the gefitinib-induced
diarrhea side effect, we suggest that curcumin might be an ideal
adjuvant for NSCLC patients during gefitinib treatment. Further
clinical studies are needed to prove our findings of curcumin in
NSCLC patients.
Materials and Methods
Ethics statement
The in vivo study protocols were approved by the Institutional
Animal Care and Use Committee of the College of Medicine,
Figure 5. Curcumin enhances the effect of gefitinib against
gefitinib-resistant relative proteins and by inducing apoptosis
activity CL1-5 xenograft tumors. (A) Western blotting analysis the
gefitinib-resistant relative proteins EGFR, AKT, c-MET, cyclin D1, and
PCNA showed the expression inhibition in curcumin alone or in
combination group of xenograft tumor tissues. Western blotting results
are represented with b-actin used as the internal control. Samples were
pooled together from three animals in each group were analyzed and
representative data are shown. (B) Western blotting analysis showing
that combination of curcumin and gefitinib inhibits the expression of
pro-caspase-8, pro-caspase-9 and pro-PARP and enhances the level of
the cleavage (c)-PARP in xenograft tumor tissues. Western blotting
results are represented with b-actin used as the internal control.
Samples were pooled together from three animals in each group were
analyzed and representative data are shown. (C) H&E staining,
immunohistochemical staining of proliferation marker PCNA and
apoptosis detection of TUNEL analysis in xenograft tumor sections
from each group indicating that curcumin inhibited the tumor cell
proliferation and enhanced the apoptotic cell death of gefitinib under a
light microscope (6400 magnification).
doi:10.1371/journal.pone.0023756.g005
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All procedures were performed under minimize suffering.
Cell lines
The human lung adenocarcinoma cell line CL1-5 was
established previously [61]. A549, H1299, H1650, H1975
(table 1), and the human bronchial epithelium cell line BEAS-2B
were obtained from American Type Culture Collection (ATCC)
(Manassas, VA). PC-9 was a kindly gift from Dr. Chih-Hsin Yang
(National Taiwan University Hospital, Taiwan). These cells were
grown in RPMI 1640 medium. The IEC-18 rat intestinal
epithelial cell line (ATCC, CRL-1589
TM) was obtained from
Bioresource Collection and Research Center (BCRC, Taiwan)
grown in DMEM medium. The media of the above contained
10% FBS (Life Technologies) with penicillin and streptomycin
(100 mg/ml) were incubated at 37uC in a humidified atmosphere
of 5% CO2.
Drug treatment
Curcumin was purchased from Sigma (St Louis, MO). Gefitinib
(ZD1839) was kindly provided by Astra-Zeneca Pharmaceuticals
(Macclesfield, UK). Stock solutions of curcumin and gefitinib were
prepared in dimethyl sulfoxide (DMSO) and stored at 220uC. The
compounds were diluted in fresh media before each experiment, and
the final DMSO concentration was lower than 0.1%. Cells were
plated in 10-cm dish at a density of 1610
6. After incubating
overnight, cells were serum starved for 24 h without FBS. Cells were
treated with 1–20 mM curcumin and/or gefitinib for 1 h in a serum-
freeconditionandthenwerestimulatedwith20 ng/mLEGF(Sigma,
MO) for 30 min. For the detection of the time course in EGFR
degradation, CL1-5 cells were plated in 10-cm dish at a density of
1610
6 for 24 h starvation. Cells were treated with 100 mg/ml
cycloheximide and 10 mM curcumin for 1 h and then added 20 ng/
ml EGF. Cells were collected at 0–60 min as indicated. For the
immunoprecipitation, cells were plated in 10-cm dish at a density of
Figure 6. Curcumin attenuates the gastrointestinal adverse effects of gefitinib in vivo. (A) The animal survival rates for each group indicate
that curcumin decreased mouse death caused by the adverse effects of gefitinib. (B) H&E staining analysis of intestine sections from each group
showing that curcumin prevents villi damage; villi lengths were quantified (bar=200 mm). Columns, mean (n=3); bars, SEM. P=0.0001 (gefitinib
versus combination). (C) Apoptosis detection by TUNEL assay using intestine sections from each group. The results indicated that curcumin reduced
the TUNEL-positive cells in the villi in the presence of gefitinib. (D) Quantification of TUNEL-positive cells as described in Materials and Methods.
Columns, mean (n=10); bars, SEM. P=0.0015 (gefitinib versus combination).
doi:10.1371/journal.pone.0023756.g006
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6 for 24 h seeding. 10 mM MG132 (Sigma, MO) was added for
1 h and then treated with 5–20 mM curcumin for further 1.5 h. For
the IEC-18, the cells were treated with gefitinib and/or curcumin or
BIRB 796 for 24 h. Cells were washed thrice with ice-cold PBS and
collected for protein extraction.
High-throughput drug screening
The herbal and natural compounds library includes the
collection of the 598 pure products and their derivatives purchased
from Sigma (St Louis, MO) and ChromaDex (Irvine, CA),
containing a range of alkaloids, sesquiterpenes, diterpenes,
pentacyclic triterpenes, sterols, and many other diverse represen-
tatives. CL1-5, A549, H1299, H1650 and H1975 cells were used
for screening by the proliferation assay; the PC9 as gefitinib-
sensitive control. For exclude the toxicity to normal cells, BEAS-
2B was used as the normal cell control.
Proliferation assay
MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bro-
mide] (Sigma, St Louis, MO) assay was performed to determine
Figure 7. Curcumin reduces gefitinib-induced gastrointestinal damage through modulating p38 activation in vitro. (A) Caspase-Glo 3/
7 assay analysis showing gefitinib induced caspase 3/7 activity in the dose-dependent manner in IEC-18 cell, but curcumin reversed this gefitinib-
induced caspase activity. Columns, mean (n=3); bars, SD. **, P,0.01. Data are representative of two independent experiments. (B) Western blotting
analysis showed that gefitinib increased active-p38 expression in a dose-dependent manner (0–20 mM). b-actin used as the internal control and the
numbers below the row of the active-p38 indicate the densitometric values normalized with the relative b-actin value. (C) Western blotting analysis
showed that curcumin and BIRB 796 decreased the gefitinib-induced p38 activation protein level in IEC-18 cell. b-actin used as the internal control
and the numbers below the row of the active-p38 indicate the densitometric values normalized with the relative b-actin value. (D) MTT assay results
showed curcumin and BIRB 796 prevent the IEC-18 cell viability from the gefitinib-induced toxic damage. Columns, mean (n=6); bars, SEM. **,
P,0.01. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0023756.g007
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IEC-18 cells were plated in 96-well plates at a density of
5610
3 cells/well. After incubating for 24 h, cells were treated
with different concentrations of curcumin and/or gefitinib for
72 h. The IEC-18 cells were treated with curcumin, BIRB 796
and/or gefitinib for 24 h incubation. 0.5 mg/ml MTT solution in
the culture medium was then added to the wells. After a further
1.5 h of incubation, the medium was removed and DMSO was
added to the plates. The color intensity was measured at 570 nm
using a multi-label plate reader (Vector3; Perkin-Elmer, USA).
Colony formation assay
CL1-5, A549 and H1975 cells were plated in 6-well plates (100
cells per well). After incubating for 24 h, the cells were treated with
1–15 mM gefitinib or 1–15 mM curcumin alone or with a
combined treatment. The cells were cultured with the agents for
5 days and then changed in the complete culture medium; the cells
were incubated for a further 9 days. Colonies were stained using
0.001% crystal violate and the number of colonies per well were
counted.
Western blot analysis
Cells and xenograft tumor tissues (100 mg) lysates were
prepared in mammalian protein extraction reagent (Pierce,
Rockford) containing protease inhibitor and phosphatase inhibitor
(Sigma, MO) and clarified by centrifugation. Protein concentra-
tions were determined by the BCA assay (Pierce, Rockford). SDS/
PAGE with 10% resolving gel was used to separate proteins
(40 mg/lane). Phospho-EGFR (Tyr1068), phospho-AKT (Ser473),
AKT, c-MET, caspase-3, caspase-8, caspase-9 and PARP
antibodies were purchased from Cell Signaling Technology
(Beverly, MA). Total EGFR, cyclin D1 and PCNA were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies were used according to the conditions recommended
by the manufacturer. Bound antibody was detected using the
Enhanced Chemiluminescence System (Santa Cruz, CA). Chemi-
luminescent signals were captured using the Fujifilm LAS 3000
system (Fujifilm, Tokyo, Japan).
Immunoprecipitation
For the detection of EGFR-ubiquitin complex, whole-cell
lysates were obtained in IP lysis buffer [50 mmol/l Tris
(pH 7.4), 150 mmol/l sodium chloride, 0.1% NP40] containing
protease inhibitor and phosphatase inhibitor (Sigma, MO) and
clarified by centrifugation. Protein concentrations were deter-
mined by the BCA assay (Pierce, Rockford). Cell lysates (1 mg)
were incubated overnight with the EGFR IP-specific mouse
monoclonal antibody (Cell Signaling, MA) at 4uC. Protein A-
Sepharose beads (Santa Cruz, CA) were added to the immuno-
precipitates and incubated at 4uC for 1 h. The beads were
Table 1. The EGFR status and ethnicities of the NSCLC cell lines used for herb compounds screening.
Cell line EGFR status Ethnicity
CL1-5 wild-type EGFR Asian
A549 wild-type EGFR Caucasian
H1299 with wild-type EGFR but p53-null Caucasian
H1650 in-frame deletions (DE746-A750) of exon 19 in EGFR, but loss of PTEN protein Caucasian
H1975 L858R substitution in exon 21 and secondary T790M substitution in exon 20 in EGFR Caucasian
PC-9 in-frame deletions (DE746-A750) of exon 19 in EGFR Asian
doi:10.1371/journal.pone.0023756.t001
Figure 8. Scheme of the curcumin regulatory effects on lung adenocarcinoma cells and intestine epithelial cells. Curcumin enhances
the antitumor effects of gefitinib on lung adenocarcinoma are hypothesized to occur through the induction of EGFR degradation, the blockage of
EGFR activation, promoting apoptosis, inhibiting the expression of c-MET, cyclin D1 and PCNA. On the other hand, curcumin attenuates the gefitinib-
induced damage on intestinal epithelial cells through modulating p38 kinase activation and cell apoptosis.
doi:10.1371/journal.pone.0023756.g008
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times in PBS with protease inhibitor and phosphatase inhibitor.
Proteins were eluted with the SDS protein sample buffer before
the Western blotting analysis with specific antibodies against
ubiquitin and EGFR (Santa Cruz, CA).
Synergy
The results from the proliferation assays were entered into the
CalcuSyn software (Biosoft, Cambridge, UK) to determine the
presence of synergy between curcumin and gefitinib in five
NSCLC cells. Combination index (CI) isobologram was calculated
in an algebraic estimate according to the method described by
Chou and Talalay [62]. CI ,1, CI=1 or CI .1 represent
synergism, additive effect or antagonism of both compounds,
respectively.
Flow cytometry
CL1-5, A549 and H1975 cells were seeded in 6-mm culture
plate at the density of 1610
5 cells per dish. After incubating for
24 h, cells were treated with 1 and 20 mM gefitinib with/without
15 mM curcumin for further 72 h. Adherent and floating cells
were both collected and resuspended in cold PBS for analysis.
Cells were stained with Annexin V-FITC Apoptosis Kit (BD
Pharmingen, USA) to monitor apoptosis cells and propidium
iodide (PI) to detect dead cells. Samples were analyzed on the FC
500 Flow Cytometry Systems (Beckman Coulter).
In vivo study protocol
The CL1-5, A549 and H1975 cells were calculated the cell
viability and cell number by trypan blue, finally 1610
6 live cells
in 100 ml HBSS were injected subcutaneously into 6-weeks-old
SCID mice (supplied by the animal center in the College of
Medicine, National Taiwan University, Taipei, Taiwan). A549
cells were stably transfected with luciferase was a kindly gift from
Professor Win-Ping Deng (Taipei Medical University, Taiwan).
Groups randomized and treatment started when tumor size was
3–5 mm. The A549 xenograft mice were randomized based on
the first bioluminescence measured after the IVIS imaging (IVIS
Imaging System 200; Xenogen Corp., Alameda, CA) were used
according to the conditions recommended by the manufacturer.
Each experimental group included at least 6 mice bearing
tumors. Curcumin for animal was prepared and suspended
properly in propylene glycol (J.T.Baker, Phillipsburg, NJ) and
gefitinib was prepared in drinking water. The dosage of 1 g/kg
curcumin alone without toxic effects to mice was used as descript
in previous study [36] and gefitinib alone (120 mg/kg) or the
combination of curcumin and gefitinib were fed through oral
administration and once daily at indicated dose for treatment.
Tumor sizes of CL1-5 and H1975 were monitored per 4 days by
electronic vernier caliper and the tumor volume was calculated
by using the formula V=0.4 6ab
2,w h e r ea and b are the longest
and shortest diameters of the tumors, respectively. The photons
volume of A549 bearing tumors were monitored per 7 days by
the IVIS imaging. The mice were sacrificed and subcutaneous
tumors were excised and half of the samples were frozen in liquid
nitrogen and stored at 280uC after several weeks of the proper
end point. Half of the tumor tissues were formalin fixed and
paraffin embedded for immunohistochemistry and routine
hematoxylin and eosin staining.
Immunohistochemical staining and cell apoptosis
detection assay
Cell proliferation analysis was performed on the paraffin-
embedded tumor tissue samples using PCNA staining. Briefly, a
rabbit anti-human PCNA polyclonal antibody (Santa Cruz, CA)
was used in the primary reaction. The DAKO EnVision System,
containing a secondary horseradish peroxidase-conjugated anti-
rabbit antibody complex, was used with 3,39-diaminobenzidine to
detect the PCNA.
Colorimetric immunohistochemical staining for apoptotic cell
death (TUNEL) was performed on the paraffin-embedded tumor
and intestine tissue sections using the In Situ Cell Death Detection
Kit, POD (Roche Diagnostics, Germany); the sections were also
counterstained with Gill’s hematoxylin. TUNEL-positive cells
were examined in 10 random fields from 4 treatment groups and
then expressed as the mean number of TUNEL-positive cells 6
SEM per high-power field (6400 magnification).
Measurement of caspase activity
Caspase activity was detected by using Caspase-Glo 3/7 assay
kit (Promega Corporation, Australia). Briefly, The IEC-18 cell was
seeded in 96-well white luminometer assay plates at a density of
1610
4 cells per well and incubated at 37uC. Cells were treated
with gefitinib and/or curcumin for 24 h. 100 ml caspase 3/7
reagents were added to each well and incubated for 1 h on rotary
shaker at room temperature. The luminescence intensity was
measured using a multi-label plate reader (Vector3; Perkin-Elmer,
USA).
Statistical analysis
Statistical analysis was performed using two-tailed Student’s t
test and significant difference was defined as P ,0.05. Data are
presented as mean 6 SD or SEM.
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